Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VCYT
VCYT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VCYT News
Veracyte Announces ENZAMET Trial Results for Genomic-Guided Therapy Decisions
19h ago
Newsfilter
Prosigna Test Guides Chemotherapy Decisions in Breast Cancer
1d ago
Newsfilter
Veracyte to Host Conference Call for 2026 ASCO Meeting
May 22 2026
Newsfilter
Veracyte Unveils ENZAMET Study Data for Prostate Cancer
May 21 2026
Newsfilter
Veracyte Secures Medicare Coverage for TrueMRD Test in Bladder Cancer
May 15 2026
Newsfilter
Veracyte Reports Strong Q1 Earnings, Shares Up 23%
May 08 2026
Fool
Veracyte Reports 21% Revenue Growth in Q1 with Quadrupled EPS
May 08 2026
NASDAQ.COM
Veracyte Reports Strong Q4 2025 Earnings with 19% Revenue Growth
Feb 26 2026
seekingalpha
Veracyte Reports Q4 Earnings Exceeding Expectations
Feb 25 2026
seekingalpha
Veracyte to Participate in Investor Conferences
Feb 19 2026
Newsfilter
Veracyte to Release Q4 and Full-Year 2025 Financial Results
Feb 04 2026
Businesswire
Veracyte Inc Shares Enter Oversold Territory
Feb 04 2026
NASDAQ.COM
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
Jan 19 2026
NASDAQ.COM
Abbott Laboratories (ABT) Forecasts Q4 2025 Revenue of $11.79 Billion, Up 7.5%
Jan 19 2026
NASDAQ.COM
Veracyte Projects 10%-13% Revenue Growth for 2026
Jan 11 2026
Businesswire
Veracyte Reports $517M Full-Year Revenue, Up 16%
Jan 11 2026
Newsfilter
Show More News
